NDA 207924 · Eli Lilly and CO
Olumiant
Baricitinib · Oral · Janus Kinase Inhibitor
NovelBreakthrough therapyLast checked: Nov 20, 2026Latest source record: Oct 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
May 31, 2018
Approved uses
6
Original approval plus efficacy supplements
Registered trials
173
61 Phase 3, 38 recruiting
FAERS reports
9,777
6,825 serious, 891 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS See full prescribing information for complete boxed warning. Increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Interrupt treatment with OLUMIANT if serious infection occurs until the infection is controlled. OLUMIANT should not be given to patients with active TB. Test for latent TB before and during therapy, except for COVID-19; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test. ( 5.1 ) Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase (JAK)...
What it is approved for
From the label in effect Oct 9, 2026.
OLUMIANT ® is a Janus kinase (JAK) inhibitor indicated for the treatment of: Moderately to severely active rheumatoid arthritis (RA) in adults who have had an inadequate response to one or more TNF blockers. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. ( 1.2 ) Severe alopecia areata (AA) in adults and pediatric patients 12 years of age and older. ( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1.3 ) 1.1 Moderately to Severely Active Rheumatoid Arthritis OLUMIANT ® is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine. 1.2 Coronavirus Disease 2019 (COVID-19) OLUMIANT is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 1.3 Severe Alopecia Areata OLUMIANT is indicated for the treatment of severe alopecia areata in adults and pediatric patients 12 years of age and older. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators,...
Mechanism: Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Baricitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 9, 2026 Supplement 10 · Efficacy LetterLabelMedication Guide
- Sep 25, 2026 Supplement 9 · Efficacy LetterLabelMedication Guide
- Jun 13, 2022 Supplement 7 · Efficacy · priority review Breakthrough therapyLetterLabel
- May 10, 2022 Supplement 6 · Efficacy · priority review LabelMedication GuideLetter
- Oct 8, 2019 Supplement 1 · Efficacy LetterLabel
- May 31, 2018 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
3 products under this application
- OLUMIANT · BARICITINIB 1MG · TABLET, ORAL · Prescription · TE AB
- OLUMIANT · BARICITINIB 4MG · TABLET, ORAL · Prescription · TE AB
- OLUMIANT · BARICITINIB 2MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Baricitinib" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Therapeutics for Moderate and Severe DenguePivotal-lookingNot yet recruiting
Oxford University Clinical Research Unit, VietnamAcademic, hospital or other
NCT07543458 · 8,800 participants (planned) · Start Oct 1, 2026 · Primary completion Jul 31, 2030
Drug: Placebo; Dexamethasone and 2 more · For: Dengue; Severe Dengue; Mosquito-Borne Diseases and 5 more
Sites: Chittagong, Bangladesh; Dhaka, Bangladesh; São Paulo, Brazil · 18 sites in all
- Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)Pivotal-lookingStatus unknown
ASST Fatebenefratelli SaccoAcademic, hospital or other
NCT04832880 · 4,000 participants (planned) · Start Apr 6, 2021 · Primary completion Mar 2022
Drug: Baricitinib Oral Tablet [Olumiant]; Remdesivir and 1 more · For: Covid19
Sites: Ancona, Italy; Aosta, Italy; Chieti, Italy · 21 sites in all
- An Extension Study in Participants With Moderate to Severe Rheumatoid ArthritisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01885078 · 2,877 participants · Start Jun 27, 2013 · Primary completion Nov 12, 2020
Drug: Baricitinib; Placebo · For: Rheumatoid Arthritis
Sites: Glendale, Arizona; Mesa, Arizona; Peoria, Arizona · 408 sites in all
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid ArthritisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03915964 · 2,659 participants · Start Apr 25, 2019 · Primary completion May 28, 2025
Drug: Baricitinib; TNF Inhibitor · For: Rheumatoid Arthritis
Sites: Flagstaff, Arizona; Gilbert, Arizona; Glendale, Arizona · 261 sites in all
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06381661 · 2,000 participants (planned) · Start Jul 9, 2026 · Primary completion Aug 9, 2028
Drug: Tocilizumab; Baricitinib and 13 more · For: Sepsis
Sites: Dijon, France; Étampes, France; Garches, France · 19 sites in all
- A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic DermatitisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03334435 · 1,645 participants · Start Mar 28, 2018 · Primary completion Sep 21, 2020
Drug: Baricitinib; Placebo · For: Atopic Dermatitis
Sites: Caba, Argentina; Buenos Aires, Argentina; Ciudad Autonoma Buenos Aires, Argentina · 185 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective786
- off label use759
- covid-19458
- rheumatoid arthritis413
- pulmonary embolism309
- pneumonia285
- headache269
- herpes zoster243
- death237
- nausea237
- deep vein thrombosis215
- arthralgia191
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 8 |
| 2018 | 314 |
| 2019 | 1,085 |
| 2020 | 846 |
| 2021 | 1,574 |
| 2022 | 1,436 |
| 2023 | 1,654 |
| 2024 | 1,408 |
| 2025 | 944 |
| 2026 | 502 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Olumiant (Baricitinib)
2024 spending
$35.4M
Beneficiaries
1,609
9,553 claims
Per beneficiary
$22,011
$104.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $18,695,163 |
| 2021 | $19,305,940 |
| 2022 | $21,134,588 |
| 2023 | $28,345,232 |
| 2024 | $35,415,629 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu AWL, Wong MM, Rayner DG, et al. · J Allergy Clin Immunol 2023 · Systematic Review, Network Meta-Analysis
- Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
Edwards SJ, Karner C, Jhita T, et al. · Health Technol Assess 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Two Phase 3 Trials of Baricitinib for Alopecia Areata.
King B, Ohyama M, Kwon O, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Taylor PC, Keystone EC, van der Heijde D, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Comparative Study
- The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.
Yoon S, Kim K, Shin K, et al. · J Eur Acad Dermatol Venereol 2024 · Meta-Analysis, Systematic Review
- Treatments for alopecia areata: a network meta-analysis.
Mateos-Haro M, Novoa-Candia M, Sánchez Vanegas G, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.